Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Chubb
Colorcon
Mallinckrodt
Fish and Richardson
McKesson
Cipla
Fuji
Citi

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021514

« Back to Dashboard

NDA 021514 describes DAYTRANA, which is a drug marketed by Noven Pharms Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the DAYTRANA profile page.

The generic ingredient in DAYTRANA is methylphenidate. There are thirty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methylphenidate profile page.
Summary for 021514
Tradename:DAYTRANA
Applicant:Noven Pharms Inc
Ingredient:methylphenidate
Patents:5
Formulation / Manufacturing:see details
Pharmacology for NDA: 021514
Medical Subject Heading (MeSH) Categories for 021514
Suppliers and Packaging for NDA: 021514
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514 NDA Noven Therapeutics, LLC 68968-5552 68968-5552-3 30 PATCH in 1 CARTON (68968-5552-3) > 9 h in 1 PATCH
DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514 NDA Noven Therapeutics, LLC 68968-5553 68968-5553-3 30 PATCH in 1 CARTON (68968-5553-3) > 9 h in 1 PATCH

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength10MG/9HR (1.1MG/HR)
Approval Date:Apr 6, 2006TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Patent:➤ Try a Free TrialPatent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Patent:➤ Try a Free TrialPatent Expiration:Oct 7, 2025Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021514

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-004 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-003 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-002 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Noven Pharms Inc DAYTRANA methylphenidate FILM, EXTENDED RELEASE;TRANSDERMAL 021514-001 Apr 6, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Merck
Teva
US Army
Harvard Business School
Chubb
Queensland Health
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.